Kite Pharma, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 132 rows in 2017. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-10-03: Reporting owner Peacock Jonathan M; Form 4; Security Director Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2017-10-03: Reporting owner Peacock Jonathan M; Form 4; Security Director Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2017-10-03: Reporting owner Peacock Jonathan M; Form 4; Security Director Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2017-10-03: Reporting owner Peacock Jonathan M; Form 4; Security Director Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-10-03 | Peacock Jonathan M Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $178.65 | 2017-10-05 | |
| 2017-10-03 | Peacock Jonathan M Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $120.77 | 2017-10-05 | |
| 2017-10-03 | Peacock Jonathan M Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $129.13 | 2017-10-05 | |
| 2017-10-03 | Peacock Jonathan M Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −8,810 0 owned after | $88.79 | 2017-10-05 | |
| 2017-10-03 | CLARK IAN T Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −17,130 0 owned after | $134.05 | 2017-10-05 | |
| 2017-10-03 | CLARK IAN T Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −8,810 0 owned after | $88.79 | 2017-10-05 | |
| 2017-10-03 | Nussbaum Ran Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $178.65 | 2017-10-05 | |
| 2017-10-03 | Nussbaum Ran Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $120.77 | 2017-10-05 | |
| 2017-10-03 | Nussbaum Ran Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $129.13 | 2017-10-05 | |
| 2017-10-03 | Nussbaum Ran Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −8,810 0 owned after | $88.79 | 2017-10-05 | |
| 2017-10-03 | Kazam Joshua A Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $178.65 | 2017-10-05 | |
| 2017-10-03 | Kazam Joshua A Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $120.77 | 2017-10-05 | |
| 2017-10-03 | Kazam Joshua A Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $129.13 | 2017-10-05 | |
| 2017-10-03 | Kazam Joshua A Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −8,810 0 owned after | $88.79 | 2017-10-05 | |
| 2017-10-03 | Humer Franz B Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −20,000 0 owned after | $123.88 | 2017-10-05 | |
| 2017-10-03 | Humer Franz B Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $129.13 | 2017-10-05 | |
| 2017-10-03 | Humer Franz B Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −8,810 0 owned after | $88.79 | 2017-10-05 | |
| 2017-10-03 | DOUMANI ROY Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −30,000 0 owned after | $173.11 | 2017-10-05 | |
| 2017-10-03 | DOUMANI ROY Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $120.77 | 2017-10-05 | |
| 2017-10-03 | DOUMANI ROY Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $129.13 | 2017-10-05 | |
| 2017-10-03 | DOUMANI ROY Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −8,810 0 owned after | $88.79 | 2017-10-05 | |
| 2017-10-03 | BONDERMAN DAVID Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $178.65 | 2017-10-05 | |
| 2017-10-03 | BONDERMAN DAVID Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $120.77 | 2017-10-05 | |
| 2017-10-03 | BONDERMAN DAVID Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $129.13 | 2017-10-05 | |
| 2017-10-03 | BONDERMAN DAVID Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −8,810 0 owned after | $88.79 | 2017-10-05 | |
| 2017-10-03 | Ruchefsky Steven B Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −200,000 0 owned after | $179.30 | 2017-10-05 | |
| 2017-10-03 | Ruchefsky Steven B Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $178.65 | 2017-10-05 | |
| 2017-10-03 | Ruchefsky Steven B Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $120.77 | 2017-10-05 | |
| 2017-10-03 | Ruchefsky Steven B Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $129.13 | 2017-10-05 | |
| 2017-10-03 | Ruchefsky Steven B Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −8,810 0 owned after | $88.79 | 2017-10-05 | |
| 2017-10-03 | CHAMPSI FARAH Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $178.65 | 2017-10-05 | |
| 2017-10-03 | CHAMPSI FARAH Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $120.77 | 2017-10-05 | |
| 2017-10-03 | CHAMPSI FARAH Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $129.13 | 2017-10-05 | |
| 2017-10-03 | CHAMPSI FARAH Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −8,810 0 owned after | $88.79 | 2017-10-05 | |
| 2017-10-03 | WITTE OWEN N. Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $173.11 | 2017-10-05 | |
| 2017-10-03 | WITTE OWEN N. Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −30,000 0 owned after | $124.91 | 2017-10-05 | |
| 2017-10-03 | WITTE OWEN N. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −17,130 0 owned after | $96.11 | 2017-10-05 | |
| 2017-10-03 | WITTE OWEN N. Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −8,810 0 owned after | $88.79 | 2017-10-05 | |
| 2017-10-03 | MOORE TIMOTHY L. Officer (EVP, Technical Operations) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −124,125 0 owned after | $135.09 | 2017-10-05 | |
| 2017-10-03 | MOORE TIMOTHY L. Officer (EVP, Technical Operations) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −96,875 0 owned after | $44.91 exercise price | 2017-10-05 | |
| 2017-10-03 | MOORE TIMOTHY L. Officer (EVP, Technical Operations) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −30,700 0 owned after | $46.09 exercise price | 2017-10-05 | |
| 2017-10-03 | Tomasello Shawn Officer (Chief Commercial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −93,000 0 owned after | $116.13 | 2017-10-05 | |
| 2017-10-03 | Tomasello Shawn Officer (Chief Commercial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −67,000 0 owned after | $63.87 exercise price | 2017-10-05 | |
| 2017-10-03 | Tomasello Shawn Officer (Chief Commercial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −38,500 0 owned after | $46.09 exercise price | 2017-10-05 | |
| 2017-10-03 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −28,833 0 owned after | $173.11 | 2017-10-05 | |
| 2017-10-03 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −29,167 0 owned after | $6.89 exercise price | 2017-10-05 | |
| 2017-10-03 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −11,069 0 owned after | $128.04 | 2017-10-05 | |
| 2017-10-03 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −5,031 0 owned after | $51.96 exercise price | 2017-10-05 | |
| 2017-10-03 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −11,550 0 owned after | $116.13 | 2017-10-05 | |
| 2017-10-03 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −14,850 0 owned after | $63.87 exercise price | 2017-10-05 | |
| 2017-10-03 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −38,500 0 owned after | $46.09 exercise price | 2017-10-05 | |
| 2017-10-03 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −3,752 0 owned after | $126.10 | 2017-10-05 | |
| 2017-10-03 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −52,500 0 owned after | $53.90 exercise price | 2017-10-05 | |
| 2017-10-03 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −2,499 0 owned after | $128.57 | 2017-10-05 | |
| 2017-10-03 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −35,000 0 owned after | $51.43 exercise price | 2017-10-05 | |
| 2017-10-03 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −14,438 0 owned after | $116.13 | 2017-10-05 | |
| 2017-10-03 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −18,562 0 owned after | $63.87 exercise price | 2017-10-05 | |
| 2017-10-03 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −38,500 0 owned after | $46.09 exercise price | 2017-10-05 | |
| 2017-10-03 | JENKINSON PAUL L Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −41,666 0 owned after | $134.96 | 2017-10-05 | |
| 2017-10-03 | JENKINSON PAUL L Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −83,334 0 owned after | $45.04 exercise price | 2017-10-05 | |
| 2017-10-03 | JENKINSON PAUL L Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −24,200 0 owned after | $46.09 exercise price | 2017-10-05 | |
| 2017-10-03 | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −116,750 0 owned after | $173.11 | 2017-10-05 | |
| 2017-10-03 | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −56,250 0 owned after | $6.89 exercise price | 2017-10-05 | |
| 2017-10-03 | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −51,563 0 owned after | $128.04 | 2017-10-05 | |
| 2017-10-03 | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −23,437 0 owned after | $51.96 exercise price | 2017-10-05 | |
| 2017-10-03 | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −28,919 0 owned after | $116.13 | 2017-10-05 | |
| 2017-10-03 | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −37,181 0 owned after | $63.87 exercise price | 2017-10-05 | |
| 2017-10-03 | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −90,600 0 owned after | $46.09 exercise price | 2017-10-05 | |
| 2017-10-03 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −44,110 0 owned after | $178.65 | 2017-10-05 | |
| 2017-10-03 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −36,284 0 owned after | $1.35 exercise price | 2017-10-05 | |
| 2017-10-03 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −121,477 0 owned after | $163.00 | 2017-10-05 | |
| 2017-10-03 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −28,034 0 owned after | $17.00 exercise price | 2017-10-05 | |
| 2017-10-03 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −51,563 0 owned after | $128.04 | 2017-10-05 | |
| 2017-10-03 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −23,437 0 owned after | $51.96 exercise price | 2017-10-05 | |
| 2017-10-03 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −28,919 0 owned after | $116.13 | 2017-10-05 | |
| 2017-10-03 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −37,181 0 owned after | $63.87 exercise price | 2017-10-05 | |
| 2017-10-03 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −90,600 0 owned after | $46.09 exercise price | 2017-10-05 | |
| 2017-10-03 | Belldegrun Arie Director, Officer (Chairman, President and CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −95,700 0 owned after | $128.04 | 2017-10-05 | |
| 2017-10-03 | Belldegrun Arie Director, Officer (Chairman, President and CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −43,500 0 owned after | $51.96 exercise price | 2017-10-05 | |
| 2017-10-03 | Belldegrun Arie Director, Officer (Chairman, President and CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −44,057 0 owned after | $116.13 | 2017-10-05 | |
| 2017-10-03 | Belldegrun Arie Director, Officer (Chairman, President and CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −56,643 0 owned after | $63.87 exercise price | 2017-10-05 | |
| 2017-10-03 | Belldegrun Arie Director, Officer (Chairman, President and CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −159,700 0 owned after | $47.42 exercise price | 2017-10-05 | |
| 2017-08-10 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,595 56,407 owned after | $53.90 exercise price | 2017-08-14 | |
| 2017-08-10 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,656 37,344 owned after | $51.43 exercise price | 2017-08-14 | |
| 2017-08-10 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 80,394 owned after | $1.35 exercise price | 2017-08-14 | |
| 2017-08-08 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −79,949 60,002 owned after | $53.90 exercise price | 2017-08-10 | |
| 2017-08-03 | MOORE TIMOTHY L. Officer (EVP, Technical Operations) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,000 146,000 owned after | $44.91 exercise price | 2017-08-04 | |
| 2017-08-01 | MOORE TIMOTHY L. Officer (EVP, Technical Operations) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 152,000 owned after | $44.91 exercise price | 2017-08-03 | |
| 2017-07-31 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,099 40,000 owned after | $51.43 exercise price | 2017-08-01 | |
| 2017-07-31 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −16,550 139,951 owned after | $53.90 exercise price | 2017-08-01 | |
| 2017-07-10 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 95,394 owned after | $1.35 exercise price | 2017-07-11 | |
| 2017-07-03 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 58,000 owned after | $6.89 exercise price | 2017-07-06 | |
| 2017-06-23 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4/A | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 110,394 owned after | $1.35 exercise price | 2017-06-27 | |
| 2017-06-23 | WITTE OWEN N. Director | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 10,000 owned after | $6.89 exercise price | 2017-06-26 | |
| 2017-06-23 | WITTE OWEN N. Director | 4 | Employee Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 0 owned after | $62.44 exercise price | 2017-06-26 | |
| 2017-06-20 | CHAMPSI FARAH Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,810 8,810 owned after | $91.21 exercise price | 2017-06-22 | |
| 2017-06-20 | BONDERMAN DAVID Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,810 8,810 owned after | $91.21 exercise price | 2017-06-22 | |
| 2017-06-20 | CLARK IAN T Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,810 8,810 owned after | $91.21 exercise price | 2017-06-22 | |
| 2017-06-20 | DOUMANI ROY Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,810 8,810 owned after | $91.21 exercise price | 2017-06-22 | |
| 2017-06-20 | Humer Franz B Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,810 8,810 owned after | $91.21 exercise price | 2017-06-22 |